EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
-3.15%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$5.56B
AUM Growth
+$5.56B
(-6%)
Cap. Flow
+$5.24M
Cap. Flow
% of AUM
0.09%
Top 10 Holdings %
Top 10 Hldgs %
25.14%
Holding
166
New
27
Increased
60
Reduced
40
Closed
11
Top Buys
| 1 |
Transmedics
TMDX
|
$47M |
| 2 |
monday.com
MNDY
|
$32.4M |
| 3 |
Toast
TOST
|
$24.8M |
| 4 |
Axsome Therapeutics
AXSM
|
$24.2M |
| 5 |
Ferguson
FERG
|
$24M |
Top Sells
| 1 |
Doximity
DOCS
|
$132M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$74M |
| 3 |
Palo Alto Networks
PANW
|
$41.7M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$36.2M |
| 5 |
XIFR
XPLR Infrastructure, LP
XIFR
|
$23.4M |
Sector Composition
| 1 | Healthcare | 41.13% |
| 2 | Technology | 24.88% |
| 3 | Industrials | 14.62% |
| 4 | Consumer Discretionary | 8.5% |
| 5 | Energy | 2.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Prothena Corp
PRTA
$452M
| $21.5M | 0.39% |
445,155
| – | – |
|
77
Pentair
PNR
$17.4B
| $21.4M | 0.38% |
330,250
+43
| +0% | +$2.78K |
|
78
Dynavax Technologies
DVAX
$1.19B
| $21M | 0.38% |
1,425,000
+398,914
| +39% | +$5.89M |
|
79
Cogent Biosciences
COGT
$1.82B
| $21M | 0.38% |
2,150,000
-1,290,796
| -38% | -$12.6M |
|
|
IMGN
80
DELISTED
Immunogen Inc
IMGN
| $20.6M | 0.37% |
1,300,000
| – | – |
|
81
Amylyx Pharmaceuticals
AMLX
$892M
| $20.4M | 0.37% |
1,116,837
| – | – |
|
82
Workday
WDAY
$62.1B
| $20.1M | 0.36% |
93,420
-40,293
| -30% | -$8.66M |
|
83
Vaxcyte
PCVX
$4.16B
| $20M | 0.36% |
+393,000
| New | +$20M |
|
84
BILL Holdings
BILL
$4.84B
| $19.9M | 0.36% |
+183,214
| New | +$19.9M |
|
85
Roivant Sciences
ROIV
$8.69B
| $19.7M | 0.35% |
1,690,300
| – | – |
|
86
Repligen
RGEN
$6.76B
| $18.9M | 0.34% |
119,000
| – | – |
|
87
BridgeBio Pharma
BBIO
$10.1B
| $18.9M | 0.34% |
716,927
-224,249
| -24% | -$5.91M |
|
88
Brookfield Renewable
BEPC
$5.91B
| $18.6M | 0.33% |
776,152
+301
| +0% | +$7.21K |
|
89
Keros Therapeutics
KROS
$651M
| $18.5M | 0.33% |
580,000
| – | – |
|
90
Rocket Pharmaceuticals
RCKT
$364M
| $18.4M | 0.33% |
898,000
| – | – |
|
91
Rollins
ROL
$27.3B
| $18.3M | 0.33% |
+490,328
| New | +$18.3M |
|
92
Novanta
NOVT
$4.01B
| $18.1M | 0.32% |
126,028
+11
| +0% | +$1.58K |
|
93
CMS Energy
CMS
$21.3B
| $17.6M | 0.32% |
331,358
+10,044
| +3% | +$533K |
|
|
XIFR
94
XPLR Infrastructure, LP
XIFR
$981M
| $17.5M | 0.31% |
588,359
-788,779
| -57% | -$23.4M |
|
95
Cytokinetics
CYTK
$5.95B
| $16.4M | 0.29% |
556,000
| – | – |
|
96
Veracyte
VCYT
$2.39B
| $16.3M | 0.29% |
732,000
| – | – |
|
97
Insmed
INSM
$30.9B
| $16M | 0.29% |
635,185
-276,918
| -30% | -$6.99M |
|
98
Houlihan Lokey
HLI
$13.8B
| $16M | 0.29% |
+149,632
| New | +$16M |
|
|
OKUR
99
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38M
| $15.8M | 0.28% |
2,078,142
+328,142
| +19% | +$2.5M |
|
100
MSCI
MSCI
$42.7B
| $15.2M | 0.27% |
29,623
-792
| -3% | -$406K |
|